Enzymatic Debridement of Deep Thermal Burns in the Russian Federation: First Experience

Since its approval in Europe a decade ago, NexoBrid((R)) enzymatic debridement of deep thermal burns has been gaining acceptance as standard practice around the world. The purpose of this study is to report the first experience with NexoBrid((R)) in the Russian Federation. During 2019-2020, we conducted a post-registration clinical study assessing the safety and treatment results of NexoBrid((R)) enzymatic debridement. The study involved 15 adult patients suffering from deep thermal burns over an area <= 15% of their total body surface area. Patients were treated with NexoBrid((R)) within 3 days of injury, followed by spontaneous or surgical wound closure. Complete eschar removal was achieved in twelve patients, 80% eschar removal in two patients, and 70% in one patient. Complete spontaneous epithelialization of wounds was achieved in 12 patients (80%) within 18 +/- 1.9 days after the start of treatment. We did not witness pathological scarring during follow-up, and there were no significant safety issues throughout the study. Early use of NexoBrid((R)) resulted in rapid, effective, and safe eschar removal with good results and sufficient preservation of viable dermis to allow for spontaneous healing in 80% of patients. These results demonstrate the ability to minimize surgical intervention and hopefully lead to better long-term scarring results.

Automated summary

Since its approval in Europe, NexoBrid enzymatic debridement has become a widely accepted standard practice for deep thermal burns treatment worldwide. This study reports the first experience with NexoBrid in the Russian Federation, showing successful eschar removal and spontaneous wound healing in most patients. The early use of NexoBrid resulted in rapid, effective, and safe treatment outcomes.